Aetna modified CPB 0145 covering alpha 1-proteinase inhibitor therapy, effective September 26, 2025. Here's what billing teams need to do.
Aetna, a CVS Health company, updated Clinical Policy Bulletin CPB 0145 governing alpha 1-proteinase inhibitor (A1PI) coverage for commercial plans. The change affects billing for HCPCS codes J0256 and J0257—the primary codes for injectable A1PI products including Aralast NP, Glassia, Prolastin-C, and Zemaira. If your practice or infusion center bills these drugs, this coverage policy update requires action before September 26, 2025.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Alpha 1-Proteinase Inhibitors |
| Policy Code | CPB 0145 |
| Change Type | Modified |
| Effective Date | September 26, 2025 |
| Impact Level | High |
| Specialties Affected | Pulmonology, Infusion Therapy, Specialty Pharmacy, Transplant Medicine |
| Key Action | Verify precertification is in place for all A1PI claims and confirm site-of-care compliance before billing J0256 or J0257 |
Aetna Alpha 1-Proteinase Inhibitor Coverage Criteria and Medical Necessity Requirements 2025
The Aetna alpha 1-proteinase inhibitor coverage policy covers J0256 and J0257 when specific medical necessity criteria are met. The core covered indication is alpha-1-antitrypsin deficiency (E88.01) — but only when billed alongside panlobular emphysema (J43.1). That pairing requirement is non-negotiable. Submit E88.01 alone and you're looking at a claim denial.
This is a critical detail your billing team needs to hardcode into your charge capture workflow. Alpha-1-antitrypsin deficiency without the associated panlobular emphysema diagnosis does not satisfy medical necessity under this policy. Both ICD-10 codes must appear on the claim.
Prior authorization is required. Precertification applies to all four branded products — Aralast NP, Glassia, Prolastin-C, and Zemaira — for all Aetna participating providers and members in applicable plan designs. Call (866) 752-7021 or fax the Statement of Medical Necessity form to (888) 267-3277. Don't wait until the infusion is scheduled. Get prior auth before the first dose.
The Site of Care Utilization Management Policy also applies here. Aetna has a separate policy governing where specialty drug infusions can be administered for reimbursement. If your practice recently moved infusions in-office from a hospital outpatient setting — or vice versa — verify your site of care aligns with Aetna's utilization management rules before billing. Noncompliance with site-of-care requirements is a separate denial risk on top of the clinical criteria requirements.
For Medicare patients, CPB 0145 doesn't apply. Aetna routes Medicare criteria to its Part B step therapy policy. If your panel includes Medicare Advantage members under an Aetna plan, confirm which policy governs before submitting.
Aetna Alpha 1-Proteinase Inhibitor Exclusions and Non-Covered Indications
CPT 38204 — management of recipient hematopoietic progenitor cell donor search and cell acquisition — is explicitly listed as not covered for indications in this policy. This tells you something about how broadly Aetna has looked at A1PI use cases. The research on A1PI for conditions like graft-versus-host disease (D89.810), ischemia-reperfusion injury (T86.xx), cystic fibrosis (E84.x), acute respiratory distress syndrome (J80), and IgA deficiency (D80.2) is active — but Aetna does not cover A1PI for these indications under CPB 0145.
The ICD-10 codes for these conditions appear in the policy's code table, but their presence signals "related to the policy" — not covered. Don't confuse a code appearing in a policy bulletin with that code being covered. These diagnoses are in the table because they've been considered and excluded.
If you're treating patients with cystic fibrosis or transplant complications and a provider wants to trial A1PI therapy, check for any applicable clinical trial or compassionate use pathways. Don't bill J0256 or J0257 for these indications under a standard Aetna commercial claim.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Alpha-1-antitrypsin deficiency with panlobular emphysema | Covered | E88.01 + J43.1, J0256, J0257 | Both ICD-10 codes required; prior auth required |
| Alpha-1-antitrypsin deficiency alone (without panlobular emphysema) | Not Covered | E88.01 | Insufficient without J43.1 |
| Cystic fibrosis | Not Covered | E84.0–E84.9 | Not a covered indication under CPB 0145 |
| Graft-versus-host disease | Not Covered | D89.810 | Related to policy but not covered |
| Ischemia-reperfusion injury (transplant complications) | Not Covered | T86.90–T86.99 | Related to policy but not covered |
| Acute respiratory distress syndrome | Not Covered | J80 | Related to policy but not covered |
| IgA deficiency | Not Covered | D80.2 | Related to policy but not covered |
| Hematopoietic progenitor cell donor management | Not Covered | CPT 38204 | Explicitly excluded |
Aetna Alpha 1-Proteinase Inhibitor Billing Guidelines and Action Items 2025
These are the steps your billing team needs to take before the September 26, 2025 effective date.
| # | Action Item |
|---|---|
| 1 | Audit your active A1PI claims and authorizations now. Pull every open claim and pending authorization for J0256 and J0257. Confirm each one has both E88.01 and J43.1 on file. Any claim missing J43.1 is a denial waiting to happen. |
| 2 | Update your charge capture templates. Build a required pairing rule: if J0256 or J0257 is on the claim, J43.1 must also be present when the clinical basis is alpha-1-antitrypsin deficiency. Flag any claim that tries to go out with E88.01 alone. |
| 3 | Initiate precertification before the first infusion — not after. Call Aetna at (866) 752-7021 or fax the SMN form to (888) 267-3277. This is not a post-service authorization. Don't schedule infusions without confirmed prior auth in hand. |
| 4 | Verify site of care for every active A1PI patient. Aetna's Site of Care Utilization Management Policy applies to these drugs. If patients are currently receiving infusions in a setting that doesn't meet Aetna's preferred site criteria, your reimbursement is at risk. Check the Aetna utilization management policy on site of care for specialty drug infusions and align before billing. |
| 5 | Train your A1PI billers on excluded diagnoses. Cystic fibrosis, ARDS, GVHD, and transplant complications are explicitly not covered under CPB 0145. If a provider orders A1PI for one of these indications, don't submit a standard commercial claim without a medical necessity review and documented exception process. The denial will come, and the appeal will be steep. |
| 6 | Confirm Medicare Advantage patients fall under the right policy. CPB 0145 governs commercial plans only. Aetna routes Medicare criteria elsewhere. Misapplying commercial criteria to an Aetna Medicare Advantage member creates a billing error — and potentially a compliance issue. If you're not sure which policy applies to a specific member's plan design, call provider relations before submitting. |
If your practice bills high volumes of A1PI and you have any uncertainty about how the site-of-care rules interact with your current infusion setup, loop in your compliance officer before September 26.
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Alpha 1-Proteinase Inhibitors Under CPB 0145
Covered HCPCS Codes (When Selection Criteria Are Met)
| Code | Type | Description |
|---|---|---|
| J0256 | HCPCS | Injection, alpha 1-proteinase inhibitor (human), not otherwise specified, 10 mg |
| J0257 | HCPCS | Injection, alpha 1-proteinase inhibitor (human), (Glassia), 10 mg |
Other HCPCS Codes Related to the Policy
| Code | Type | Description |
|---|---|---|
| S9346 | HCPCS | Home infusion therapy, alpha-1-proteinase inhibitor (e.g., Prolastin); administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment |
Not Covered CPT Codes
| Code | Type | Description | Reason |
|---|---|---|---|
| 38204 | CPT | Management of recipient hematopoietic progenitor cell donor search and cell acquisition | Not covered for indications listed in CPB 0145 |
Other CPT Codes Related to the Policy
| Code | Type | Description |
|---|---|---|
| 38207 | CPT | Transplant preparation of hematopoietic progenitor cells |
| 38208 | CPT | Transplant preparation of hematopoietic progenitor cells |
| 38209 | CPT | Transplant preparation of hematopoietic progenitor cells |
| 38210 | CPT | Transplant preparation of hematopoietic progenitor cells |
| 38211 | CPT | Transplant preparation of hematopoietic progenitor cells |
| 38212 | CPT | Transplant preparation of hematopoietic progenitor cells |
| 38213 | CPT | Transplant preparation of hematopoietic progenitor cells |
| 38214 | CPT | Transplant preparation of hematopoietic progenitor cells |
| 38215 | CPT | Transplant preparation of hematopoietic progenitor cells |
| 82103 | CPT | Alpha-1-antitrypsin; total |
| 82104 | CPT | Alpha-1-antitrypsin; phenotype |
Key ICD-10-CM Diagnosis Codes
| Code | Description | Coverage Status |
|---|---|---|
| E88.01 | Alpha-1-antitrypsin deficiency | Covered only when billed with J43.1 |
| J43.1 | Panlobular emphysema (panacinar emphysema) | Required paired diagnosis with E88.01 |
| D80.2 | Selective deficiency of immunoglobulin A [IgA] | Related — not a covered indication |
| D89.810 | Acute graft-versus-host disease | Related — not a covered indication |
| E84.0–E84.9 | Cystic fibrosis (various manifestations) | Related — not a covered indication |
| J80 | Acute respiratory distress syndrome | Related — not a covered indication |
| T86.90–T86.99 | Complications of transplanted organ and tissue (ischemia-reperfusion injury) | Related — not a covered indication |
Get the Full Picture for CPT 38204
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.